Abstract
The impact of multiple episodes of clinically significant cytomegalovirus infection (csCMVi) on clinical outcomes during pre-emptive CMV monitoring in allogeneic hematopoietic stem cell transplant recipients (HCT) is not well understood.
We performed a retrospective cohort study of all consecutive patients undergoing their first allogeneic HCT at Duke between January 1, 2009 and December 31, 2013, during an era of pre-emptive CMV monitoring, prior to widespread use of letermovir prophylaxis. Consensus definitions were utilized for refractory and resistant CMV infection, bacteremia, invasive fungal disease, and renal dysfunction. The Kaplan-Meier method was used to estimate survival.
Three hundred eighty-eight adult patients underwent allogeneic HCT during the study time period with 91 patients (23%) having one episode of csCMVi and 79 patients (20%) having ≥ one episode of csCMVi. Risk factors for multiple episodes of csCMVi included having a transplant from a matched unrelated donor, cord blood as HCT source, and graft-versus-host disease prophylaxis with highly T-cell suppressive agents such as alemtuzumab. Patients with multiple episodes tended to develop csCMVi earlier post-transplant and were more likely to have CMV disease and to develop resistant CMV infection. There was no difference in rates of refractory CMV infection, bacteremia, invasive fungal disease, or survival. However, patients with multiple episodes of csCMV had reduced one-year relapse-related mortality compared to patients with one csCMVi episode.
Competing Interest Statement
S.M.T. reports membership on the following American Joint Committee on Cancer: Breast Panel, Neuroendocrine Tumors Committee, and Evidence-Based Medicine Committee. B.D.A. reports membership on the Advisory Board for Letermovir for Merck & Company and being a site principal investigator for Shire and Takeda Pharmaceuticals' for Maribavir Clinical Trial.
Funding Statement
Yes
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Duke Health IRB.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
Data Availability
All relevant data are within the manuscript and its Supporting Information files.
